Advice
Following a resubmission
levetiracetam (Keppra) is accepted for use within NHS Scotland as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
In the pivotal study, addition of levetiracetam to existing anticonvulsant therapy was more effective than addition of placebo in reducing the number of days on which myoclonic seizures occurred.
Download detailed advice80KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 395/07
- Indication:
- adjunctive therapy in treatment of myclonic seizures in adults and adolescents from 12 years of age with juvenile muclonic epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 11 February 2008